Form 8-K - Current report:
SEC Accession No. 0000950170-23-008457
Filing Date
2023-03-16
Accepted
2023-03-16 16:11:02
Documents
14
Period of Report
2023-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oric-20230316.htm   iXBRL 8-K 75563
2 EX-99.1 oric-ex99_1.htm EX-99 255707
3 GRAPHIC img48504584_0.jpg GRAPHIC 3609
  Complete submission text file 0000950170-23-008457.txt   479703

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oric-20230316_pre.xml EX-101.PRE 11564
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oric-20230316_lab.xml EX-101.LAB 19315
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oric-20230316.xsd EX-101.SCH 2480
8 EXTRACTED XBRL INSTANCE DOCUMENT oric-20230316_htm.xml XML 4899
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 23738881
SIC: 2834 Pharmaceutical Preparations